Novel model reveals how genomic instability arises in histologically benign tissue

Understanding which cells give rise to which areas of cancer can improve our understanding of how a tumor has grown and developed, including how it has changed genetically, over time. This has been made possible using a new technique called spatial transcriptomics, which allows scientists to see what genetic changes take place without breaking up the tissue they're looking at. This adds a new dimension which researchers have now used to reveal which cells have mutated and where within the ecosystem of an organ.

Current techniques for studying the genetics of cells within tumors involve taking a sample from the cancerous area and analyzing the DNA of those cells. The problem is that many cancers, such as prostate cancer, are three dimensional, which means that any one sample would only give a small snapshot of the tumor.

In a new study published in Nature and funded by Cancer Research UK, the researchers used spatial transcriptomics to create a cross-sectional map of a whole prostate, including areas of healthy and cancerous cells. By grouping cells according to similar genetic identity, they were surprised to see areas of supposedly healthy tissue that already had many of the genetic characteristics of cancer. This finding was surprising because of both the genetic variability within the tissue as well as the large number of cells that would be considered healthy, but which contained mutations usually identified with cancerous cells.

Prostate tissue is three-dimensional, and like most organs that can develop cancer we still have much to learn about what cellular changes cause cancer and where it starts. One thing we are fairly confident of is that it starts with genetic mutations."

Alastair Lamb, Nuffield Department of Surgical Sciences, University of Oxford

"We have never had this level of resolution available before, and this new approach revealed some surprising results. For example, we have found that many of the copy number events we previously thought to be linked specifically to cancer are actually already present in benign tissue. This has big implications for diagnosis and also potentially for deciding which bits of a cancer need treating."

Professor Joakim Lundeberg of KTH Royal Institute of Technology, said: "Mapping thousands of tissue regions in a single experiment is an unprecedented approach to deconvolute the heterogeneity of tumors and their microenvironment. This high-resolution view impacts our way of addressing complex ecosystems such as cancer. The possibility to identify early events is particularly exciting going forward."

Furthermore, the researchers analyzed more than 150,000 regions in three prostates, two breast cancers, some skin, a lymph node and some brain tissue, and developed an algorithm to track groups of cells with similar genetic changes -clones- in their precise location. This approach enabled them to zoom right in from visible tissue through microscopic multi-cellular structures and right into the genes themselves, while keeping hold of the overall landscape of tissue.

Source:
Journal reference:

Erickson, A. et al. (2022) Spatially resolved clonal copy number alterations in benign and malignant tissue. Nature. doi.org/10.1038/s41586-022-05023-2.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New NCCN guidelines include expanded genetic risk assessment for various cancers